Company Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1849 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 88,000 |
| CEO | Albert Bourla |
Contact Details
Address: 66 Hudson Boulevard East New York, New York 10001-2192 United States | |
| Phone | 212 733 2323 |
| Website | pfizer.com |
Stock Details
| Ticker Symbol | PFE |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000078003 |
| CUSIP Number | 717081103 |
| ISIN Number | US7170811035 |
| Employer ID | 13-5315170 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board and Chief Executive Officer |
| David M. Denton | Chief Financial Officer and Executive Vice President |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research and Development |
| Douglas M. Lankler | Executive Vice President and General Counsel |
| Jennifer B. Damico | Senior Vice President, Controller and Principal Accounting Officer |
| Lidia L. Fonseca | Executive Vice President and Chief Digital and Technology Officer |
| Francesca M. DeMartino | Chief Investor Relations Officer |
| Rady A. Johnson | Executive Vice President and Chief Compliance, Quality and Risk Officer |
| Andreas J. Panayiotou | Global Chief Marketing Officer |
| Payal Sahni Becher | Chief People Experience Officer and Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 8-K | Current Report |
| Sep 13, 2024 | SC TO-I/A | Filing |
| Aug 22, 2024 | SC TO-I/A | Filing |
| Aug 15, 2024 | UPLOAD | Filing |
| Aug 12, 2024 | SC TO-I | Filing |
| Aug 5, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 5, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | SC TO-C | Filing |